Therapeutic Claims in Cannabidiol (CBD) Marketing Messages on Twitter
- PMID: 35096472
- PMCID: PMC8794048
- DOI: 10.1109/bibm52615.2021.9669404
Therapeutic Claims in Cannabidiol (CBD) Marketing Messages on Twitter
Abstract
Although the U.S. FDA has only approved exactly one cannabidiol (CBD) drug product (specifically to treat seizures), CBD products are proliferating rapidly through different modes of usage including food products, cosmetics, vaping pods, and supplements (typically, oils). Despite the FDA clearly warning consumers about unproven health claims made by manufacturers selling CBD products over the counter, the CBD market share was nearly 3 billion USD in 2020 and is expected to top 55 billion USD in 2028. In this context, it is important to assess the presence of health claims being made on social media, especially claims that are part of marketing messages. To this end, we collected over two million English tweets discussing CBD themes. We created a hand-labeled dataset and built machine learned classifiers to identify marketing tweets from regular tweets that may be generated by consumers. The best classifier achieved 85% precision, 83% recall, and 84% F-score. Our analyses showed that pain, anxiety disorders, sleep disorders, and stress are the four main therapeutic claims made constituting 31.67%, 27.11%, 13.77%, and 10.37% of all medical claims made on Twitter, respectively. Also, more than 93% of advertised CBD products are edibles or oil/tinctures. Our effort is the first to demonstrate the feasibility of surveillance of marketing claims for CBD products. We believe this could pave way for more explorations into this indispensable task in the current landscape of social media driven health (mis)information and communication.
Keywords: CBD; Twitter; cannabidiol; classification; health claims; social media surveillance; text mining.
Figures
References
- 
    - Grinspoon P, “Cannabidiol (CBD)—what we know and what we don’t,” Harvard Health Blog, vol. 24, 2018.
 
- 
    - W. H. Organization, “Cannabidiol (CBD) pre-review report agenda item 5.2,” in Expert Committee on Drug Dependence Thirty-ninth Meeting, Geneva, 2017.
 
Grants and funding
LinkOut - more resources
- Full Text Sources
 
        